Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.

ABSTRACT:

Objective

The inability to successfully treat women with ovarian cancer is due to the presence of metastatic disease at diagnosis and the development of platinum resistance. Ovarian cancer metastasizes throughout the peritoneal cavity by attaching to and invading through the mesothelium lining the peritoneum using a mechanism that involves α4β1 integrin and its ligand (vascular cell adhesion molecule) VCAM-1. Integrin α4β1 expression on tumor cells is known to confer protection from therapy in other cancers, notably multiple myeloma. We evaluated the role of α4β1 integrin in response to platinum-based therapy in a mouse model of peritoneal ovarian cancer metastasis by treatment with a humanized anti-α4β1 integrin function-blocking antibody.

Methods

Integrin α4β1 expression o

SUBMITTER: Scalici JM 

PROVIDER: S-EPMC3939448 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature